Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 2, 2010, Pages 203-211

  Veliotes, Demetri G A ^a   Norton, Gavin R ^a   Correia, Raul J ^a   Strijdom, Hans ^b   Badenhorst, Danelle ^a   Brooksbank, Richard ^a   Woodiwiss, Angela J ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GELATINASE A; ISOPRENALINE; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADRENERGIC ACTIVITY; ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CROSS LINKING; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CELL; HEART WEIGHT; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-AGONISTS; ALDOSTERONE ANTAGONISTS; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; ISOPROTERENOL; MATRIX METALLOPROTEINASE 2; MYOCARDIAL CONTRACTION; MYOCARDIUM; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ALDOSTERONE; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 77955980931     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e92a01     Document Type: Article

References (46)

1. Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Cardiac function as related to adrenergic activity in hypertensive left ventricular hypertrophy. J Clin Hypertens. 1987;3:203-210.
2. Schlaich MP, Keye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565.
3. Esposito G, Rapacciuolo A, Naga Prasad SV et al. Genetic alterations that inhibit in vivo pressure overload hypertrophy to prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
4. Badenhorst D, Veliotes D, Maseko M, et al. (3-Adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension. 2003;41:499-504.
5. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2009; 119:e391-e479.
6. Bakris GL, Sowers JR. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk? Hypertension. 2004;43:941-942.
7. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principle outcomes of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
8. Veliotes DGA, Woodiwiss AJ, Deftereos DAJ, et al. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by b-adrenoreceptor activation. Hypertension. 2005;45:914-920.
9. Menon B, Singh M, Singh K. Matrix metalloproteinases mediate beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes. Am J Physiol Cell Physiol. 2005;289:C168-C176.
10. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 1999;85:364-376.
11. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001;103:2303-2309.
12. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest. 2005;115:565-571.
13. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest. 2003;111:1497-1504.
14. Singh K, Xiao L, Remondino A, et al. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol. 2001;189:257-265.
15. Osadchii OE, Norton GR, McKechnie R, et al. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic b-adrenoreceptor activation. Am J Physiol. 2007;292:H1898-H1905.
16. Tamura T, Onodera T, Said S, et al. Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. JMol Cell Cardiol. 1998;30:2175-2181.
17. Majane OHI, Vengethasamy L, du Toit EF, et al. Dietary-induced obesity hastens the progression from concentric cardiac hypertrophy to pump dysfunction in spontaneously hypertensive rats. Hypertension. 2009;54: 1376-1383.
18. Norton GR, Woodiwiss AJ, Gaasch WH, et al. Heart failure in pressure overload hypertrophy: the relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol. 2002;39:664-671.
19. Woodiwiss AJ, Tsotetsi OJ, Sprott S, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation. 2001;103:155-160.
20. Norton GR, Tsotetsi J, Trifunovic B, et al. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation. 1997;96: 1991-1998.
21. Trifunovic B, Norton GR, Duffield MJ, et al. An androgenic steroid decreases left ventricular compliance in rats. Am J Physiol. 1995;258: H1096-H1103.
22. Woodiwiss AJ, Norton GR. Exercise-induced cardiac hypertrophy is associated with an increased myocardial compliance. J Appl Physiol. 1995;78:1303-1311.
23. Tsotetsi OJ, Woodiwiss AJ, Netjhardt M, et al. Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Hypertension. 2001;38:846-851.
24. Tyagi SC, Matsubara L, Weber KT. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem. 1993;26:191-198.
25. Polyakova V, Hein S, Kostin S, et al. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol. 2004;44:1609-1618.
26. Agarwala S, Kalil RE. Axotomy-induced neuronal death and reactive astrogliosis in the lateral geniculate nucleus following a lesion of the visual cortex in the rat. J Comp Neurol. 1998;392:252-263.
27. Hearse DJ, Stewart DA, Braimbridge MV. Hypothermic arrest and potassium arrest: metabolic and myocardial protection during elective cardiac arrest. Circ Res. 1975;36:481-489.
28. Bub G, Camelliti P, Bollensdorff C, et al. Measurement and analysis of sarcomere length in rat cardiomyocytes in situ and in vitro. Am J Physiol. 2010;298:H1616-H1625.
29. Gerdes AM, Kellerman SE, Moore JA, et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 1992;86:426-430.
30. Diez C, Simm A. Gene expression in rod shaped cardiac myocytes, sorted by flow cytometry. Cardiovasc Res. 1998;40:530-537.
31. King MK, Coker ML, Goldberg A, et al. Selective matrix metal-loproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003;92:177-185.
32. Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427.
33. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone receptor blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106:2967-2972.
34. Badenhorst D, Maseko M, Tsotetsi OJ, et al. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res. 2003;51: 632-641.
35. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
36. Zannad F, Alla F, Dousett B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized ALdactone Evaluation Study (RALES). Circulation. 2000; 102:2700-2706.
37. Olson MW, Gervasi DC, Mobashery S, et al. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem. 1997;272: 29975-29983.
38. Siwik DA, Kuster GM, Brahmbhatt JV, et al. EMMPRIN mediates b-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. JMol Cell Cardiol. 2008;44:210-217.
39. Ruangpanit N, Chan D, Holmbeck K, et al. Gelatinase A (MMP-2) activation by skin fibroblasts: dependence on MT1-MMP expression and fibrillar collagen form. Matrix Biology. 2001;20:193-203.
40. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metal-loproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation. 2004;109:2143-2149.
41. Mujumdar VS, Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decom-pensatory heart failure. JHypertens. 1999;17:261-270.
42. Fortuno MA, Zalba G, Ravassa S, et al. p53-Mediated upregulation of BAX gene transcription is not involved in BAX-alpha protein over expression in the left ventricle of spontaneously hypertensive rats. Hypertension. 1999;33:1348-1352.
43. Kajstura J, Cheng W, Sarangarajan R, et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol. 1996;271:H1215-H1228.
44. McCrossan ZA, Billeter R, White E. Transmural changes in size, contractile and electrical properties of SHR left ventricular myocytes during compensated hypertrophy. Cardiovasc Res. 2004;63:283-392.
45. Diffee GM, Nagle GF. Exercise training alters length dependence of contractile properties in rat myocardium. J Appl Physiol. 2003;94: 1137-1144.
46. He J-Q, Conklin MW, Foell JD, et al. Reduction in density of transverse tubules and L-type Ca2+ channels in canine tachycardia-induced heart failure. Cardiovasc Res. 2001;49:298-307.